IMPORTANCE Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects.
C linical trial National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31, analyzed jointly with the North Central Cancer Treatment Group (NCCTG) N9831, established the benefit of adding trastuzumab, a monoclonal antibody targeting the ERBB2/HER2 protein, to standard chemotherapy in patients with early stage ERBB2/ HER2-positive breast cancer. However, only about one-third to one-half of patients benefit from this therapy in advanced or adjuvant settings, respectively. 1, 2 Although treatment is generally well tolerated, its high cost, associated cardiotoxic effects, and the availability of promising alternatives warrant an attempt to identify patients who will not benefit. Although many mechanisms have been attributed to the success of trastuzumab, the original patent described 2 primary potential mechanisms. First, by binding to ERBB2/ HER2 on the cancer cell membrane, it prevents ERBB2/HER2 dimerization, blocks downstream signaling, and subsequently blocks proliferation. Second, it triggers the host immune system to attack and kill trastuzumab-bound tumor cells. This immune response, known as antibody-dependent cellmediated cytotoxic effect (ADCC), is initiated when the FCγ receptor on natural killer cells (NK) binds to the Fc portion of trastuzumab. As a result, NK cells release factors including IFN-γ, perforins, and granzymes, which cause tumor cell death via apoptosis. A similar process, known as antibodydependent cellular phagocytosis (ADCP), is initiated when the FCγ receptor on a macrophage binds to trastuzumab and results in tumor cell death by phagocytosis.
Early studies in ERBB2/HER2-positive breast cancer cell lines demonstrated potent ADCC caused by trastuzumab in vitro.
3 Experiments in mice have demonstrated reduced trastuzumab efficacy if the Fc fragment is removed from the antibody or if the mouse is deficient in FCγ receptors. 4, 5 In addition, an increase in the infiltration of lymphoid cells into tumor samples was observed after trastuzumab treatment compared with paired pretreatment samples. 6 Collectively, these findings support a strong role of ADCC or ADCP in the mechanism of trastuzumab efficacy. Additional preclinical studies have demonstrated an association of single-nucleotide polymorphisms in the genes encoding FCγ receptors with the strength of the immune response. Many studies have focused on position 158 of FCGR3A, which encodes a valine or phenylalanine, and position 131 of FCGR2A, which encodes a histidine or arginine (reviewed in Mellor et al). 7 In vitro ADCC assays demonstrated greater trastuzumab-mediated ADCC with the FCGR3A-158 valine (V)/V genotype and a trend for association with the FCGR2A-131 histadine (H)/H genotype. 8 Analyses of paired pretreatment and posttreatment peripheral blood mononuclear cells (PBMCs) demonstrated more differential changes in gene expression from patients with the V/V or H/H genotypes than did patients with phenylalanine (F)/F or arginine (R)/R genotypes, indicating a difference in the molecular response to trastuzumab according to genotype. 9 These observations are consistent with the observation that the FCγRIIA-131H and FCγRIIIA-158V have a higher affinity to immunoglobin (IgG) than the proteins encoded by alternate alleles. 10 Cells bearing the high-affinity alleles mediate ADCC more effectively.
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Clinical studies using therapeutic monoclonal antibodies such as rituximab for the treatment of lymphoma and cetuximab for the treatment of colon cancer have shown association of the FCGR3A and FCGR2A genotypes with patient outcomes.
11 To explore this discrepancy, we retrospectively examined the FCGR3A-158 and FCGR2A-131 genotypes in all available pretreatment blood specimens from NSABP B-31. Our prespecified primary objective was to determine whether patients with breast cancer with FCGR3A-158 V/V or FCGR3A 158 V/F received greater benefit from trastuzumab than patients with the FCGR3A F/F genotype.
Methods

Patient Cohort
Detailed patient characteristics, eligibility criteria, adverse events, and clinical trial results have previously been reported. 2, 19, 20 The NSABP B-31 trial randomly assigned women with surgically resected node-positive ERBB2/HER2-positive breast cancer to treatment with doxorubicin and cyclophosphamide followed by paclitaxel (ACT) or the same regimen with the addition of 1 year of weekly trastuzumab (ACTH 
Genotyping
Whole blood was collected before treatment and stored at −80°C . Participant DNA was prepared from 100 μL of whole blood using the Mag-Bind Blood DNA HDQ kit (Omega Biotek) and quantified with picogreen (ThermoFisher). Genotyping of rs1801274 (FCGR2A-131 R/H) and rs396991 (FCGR3A-158 V/F) was performed using iPLEX Pro chemistry and mass spectrometry (Agena) according to the manufacturer's instructions. Nested polymerase chain reaction was used for FCGR3A-158 to achieve specificity against its homologue FCGR3B. Genotypes were determined with Typer software using default settings after autoclustering (Agena). Two-thirds of the rs396991 assays were performed in duplicate. Bacterial artificial chromosome clones RP11-5K23 (FCGR3A), RP11-100D4 (FCGR3B), and an equimolar mixture of the 2 were used as controls to ensure the rs396991 primers specifically amplified the 3A homologue. Detailed reaction conditions and primer sequences are provided in eMethods in the Supplement. All assays were performed blinded to clinical outcome using deidentified specimens.
Statistical Methods
The use of patient blood specimens and a detailed statistical analysis plan were approved by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) before starting the current investigation. The primary end point for survival analyses was disease-free survival. Disease-free survival events included local, regional, and distant recurrence; contralateral breast cancer; a second primary cancer; or death from any cause. Follow-up included events recorded before June 30, 2012. In 2005, during a planned joint analysis with NCCTG-N9831, the early-stopping boundary was reached and patients on the ACT arm were offered trastuzumab. Patients who crossed over to the trastuzumab arm were censored at the time of crossover. The treatment benefit and prognostic effect for each genotype was first investigated using the KaplanMeier method and treatment arms were compared using logrank tests. As the primary aim, FCGR3A genotype by treatment interaction was tested using proportional hazard regression models. For purposes of the interaction tests, the highaffinity genotypes were combined (FCGR3A-158 V/V or V/F vs F/F). Similar analyses were performed for FCGR2A as a secondary objective. Survival analyses provided here were adjusted for estrogen receptor (ER) (positive or negative), progesterone receptor (PR) (positive or negative), age (years), tumor size (cm), and nodal status (1-3, 4-9, or ≥10 positive lymph nodes). Univariable models are reported in the Supplement or are clearly indicated as such. Missing values in the covariates resulted in the exclusion of 8 cases for multivariable analyses of FCGR3A and 7 cases for FCGR2A. The Fisher exact test was used to test deviation from Hardy Weinberg Equilibrium and to test the association of genotype with clinical characteristics. Linkage disequilibrium was investigated in the subset of patients with results for both assays. All statistical tests were 2-sided and performed in R.
Results
Patient Characteristics
Among 2006 eligible patients with follow-up and informed consent, pretreatment blood specimens were available for 1253 and DNA was successfully prepared for 1251. Details regarding the reasons for sample loss are shown in eFigure 1 in the Supplement. Clinical and pathological characteristics were well balanced in the treatment arms of the study population and closely resembled the entire B-31 cohort (eTable 1 and eTable 2intheSupplement). Median follow-up time was 8.2 years in the genotyped samples. The disease-free survival probability at 3, 5, and 8 years was 74% (95% CI, 71%-79%), 66% (95% CI, 62%-71%), and 58% (95% CI, 54%-63%) in patients who received ACT and 86% (95% CI, 83%-89%), 82% (95% CI, 79%-85%), and 78% (95% CI, 74%-81%) in patients who received ACTH. Addition of trastuzumab significantly improved patient outcome (hazard ratio [HR], 0.46; 95% CI, 0.37-0.57; P < .001).
Genotyping Results
Of 883 assays performed in duplicate, 3 discordances were observed (0.3%) for FCGR3A-158 (rs396991). These 3 observations were excluded from further analysis. Approximately 2% of FCGR2A-131 and 7% of FCGR3A-158 assays failed default genotyping quality controls in the Typer software, yielding 21 and 87 missing values, respectively. Some of the FCGR3A reactions excluded by the software may actually represent heterozygous patients with 3 germline copies of the gene. 21 However, these wells are indistinguishable from wells with contamination or poor reaction conditions and their expected frequency of 2.5% limits our power to detect meaningful clinical significance. For these reasons, any sample that failed quality control was eliminated. Thirteen samples failed both assays, suggesting poor-quality DNA. The patients genotyped showed 25% H/H, 49% H/R, and 26% R/R alleles for FCGR2A-131 and 46% F/F, 42% F/V, and 12% V/V for FCGR3A-158. Both loci conform to the Hardy Weinberg Equilibrium in our data. In 1156 specimens with both assays successful, linkage disequilibrium analysis indicated the FCGR3A and FCGR2A genes are strongly linked (D′ = 0.30; P < .001) as expected from their close genomic proximity and previous studies.
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FCGR Polymorphisms and Clinical Characteristics
FCGR3A-158 single-nucleotide polymorphisms were not associated with nodal status, ER, PR, tumor size, or race (eTable 3intheSupplement). However, patients with the homozygous V/V genotype tended to be older (P < .001). The mean age
FCGR3A Polymorphism and Trastuzumab Efficacy
Patients with genotypes that included the higher-affinity alleles FCGR3A-158 V/V or V/F received greater benefit from trastuzumab (HR, 0.31; 95% CI, 0.22-0.43; P < .001) than patients who were homozygous for the low-affinity allele (HR, 0.71; 95% CI, 0.51-1.01; P = .05) ( Figure 1A and B). Genotype by treatmentinteraction test indicates an association between FCGR3A-158 and benefit from trastuzumab (P < .001). In an exploratory analysis, the FCGR3A-158, high-affinity V/V homozygous patients received the most benefit (HR, 0.12; 95% CI, 0.05-0.28; P < .001), heterozygous F/V patients received intermediate benefit (HR, 0.34; 95% CI, 0.23-0.48; P < .001), and homozygous low-affinity F/F patients received the least benefit (HR, 0.71; 95% CI, 0.51-1.01; P = .05) (Figure 2 ). Similar results were observed using univariable models. The box size is proportional to the precision. ACTH, doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab; HR, hazard ratio.
FCGR2A Polymorphism and Trastuzumab Efficacy
The FCGR2A polymorphism demonstrated the trends expected from preclinical models ( Figure 2 ). FCGR2A-131, highaffinity H/H homozygous patients received the most benefit (HR, 0.31; 95% CI, 0.19-0.49; P < .001), heterozygous H/R patients received intermediate benefit (HR, 0.50; 95% CI, 0.37-0.68; P < .001), and homozygous low-affinity R/R patients received the least benefit (HR, 0.57; 95% CI, 0.35-0.92; P = .02) (Figure 2 ). However, treatment interaction tests indicate no difference in trastuzumab efficacy according to FCGR2A-131 (P = .24 for H/H or H/R vs R/R).
FCGR Polymorphism and Prognosis
In an exploratory analysis in the ACT arm, patients with FCGR3A-158 V/F or V/V had worse prognosis than patients with F/F (HR, 1.57; 95% CI, 1.15-2.14; P = .005) (eFigure 2 in the Supplement). On the other hand, in the ACTH arm, patients with FCGR3A-158 V/F or V/V had better prognosis than patients with F/F (HR, 0.68; 95% CI, 0.48-0.96; P = .03). Univariable models demonstrated similar results. FCGR2A-131 genotypes showed no evidence of prognosis in either arm.
Combined Genotypes
Additional exploratory analyses revealed approximately 15% of the population are homozygous for both of the low-affinity alleles (FCGR3A-158 F/F and FCGR2A-131 R/R; n = 179) ( Figure 3 ). Trastuzumab appears less effective in these patients (HR, 0.81; 95% CI, 0.41-1.58; P = .53). However, treatment interaction tests of this population were not significant (P = .06 for F/F and R/R vs others).
Discussion
Analysis of FCGR3A-158 polymorphism in NSABP B-31 demonstrated differential trastuzumab benefit predicted by preclinical models, studies of other antibodies, and smaller studies of trastuzumab in the metastatic and neoadjuvant settings. These results indicate that ADCC may play a substantial component in the efficacy of trastuzumab for the treatment of breast cancer in the adjuvant setting; ADCC also activates tumor-antigen-specific cellular immunity via intercellular crosstalk among NK and dendritic cells, which may also enhance the efficacy of anti-ERBB2/ HER2 therapy.
22,23
We also observed that the FCGR2A-131 polymorphism showed the expected trend for trastuzumab benefit but treatment interaction tests indicated no evidence of differential trastuzumab treatment effect according to FCGR2A genotypes. Perhaps this may be owing to the lack of expression of FCγRIIa on NK cells because NK cells are thought to be the main effectors of ADCC; although cytotoxic effects mediated through other effector cells via FCγRIIa have been reported. 24 Our observation that the significant differential benefit from trastuzumab was limited to the FCGR3A-158 polymorphism and was not seen in the FCGR2A-131 single-nucleotide polymorphisms may also be owing to the fact that FCγRIIIa-158V was found to bind to IgG1 immune complexes at low concentrations but did not bind to FCγRIIIa-158F. Conversely, no binding differences were detected between FCγRIIa-131H and 131R at low IgG1 concentrations.
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Our results differ from recent reports from the NCCTG-N9831 17 and BCIRG-006 trials, 18 which found no association of FCGR3A-V158 and benefit from trastuzumab. These trials also examined the addition of trastuzumab to ACT in the adjuvant treatment of ERBB2/HER2-positive breast cancer and differed from NSABP B-31 primarily in the timing of the treatments. Both studies had sample sizes remarkably similar to our own and demonstrated substantial benefits from the addition of trastuzumab to chemotherapy. The methodologies used were rigorous: BCIRG-006 measured each single-nucleotide polymorphisms in quadruplicate (duplicate measurements on 2 platforms) and NCCTG-N9831 had 100% concordance in onethird of the population measured in duplicate. However, both of the previous FCGR studies suffered from sampling bias. In the BCIRG-006 study, the 1286 patients who were genotyped did not show significant benefit from trastuzumab (HR, 0.84; 
ACT ACTH
ACT indicates doxorubicin and cyclophosphamide followed by paclitaxel; ACTH, doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab; DFS, disease-free survival; HR, hazard ratio; M, multivariable; U, univariable.
Polymorphisms in FCGR3A and Degree of Trastuzumab Benefit
Original Investigation Research jamaoncology.com (Reprinted) JAMA Oncology March 2017 Volume 3, Number 3P = .19) and the authors acknowledged that they cannot exclude a contribution of FCGR polymorphisms to the outcome of trastuzumab-treated patients due to the sampling bias.
FCGR3A-158 also deviated from the Hardy Weinberg Equilibrium in the BCIRG-006 study. Blood for genotyping was collected from NCCTG-N9831 patients after the trial closed to accrual, leading to differences from the study population and the intent-to-treat population. The NCCTG-N9831-genotyped cohort included a greater proportion of trastuzumab-treated patients, less nodal disease, smaller tumors, a greater number of hormone receptor-positive tumors, and patients who were slightly older than the entire NCCTG-N9831 cohort. As a result, the genotyped patients had a substantially better diseasefree survival than the entire NCCTG-N9831 cohort. For both studies, these biases resulted in a loss of events and as a result reduced power to detect genotype-treatment interaction.
In our exploratory analysis, the observation that the FCGR3A low-affinity allele was associated with a better prognosis than the high-affinity allele in the ACT arm was unexpected. Chemotherapy has been shown to induce an immune response and possibly the differential binding affinity of FCγRIIIa-158V and FCγRIIIa-158F proteins to intrinsic antibodies may result in differential benefit from chemotherapy. Polymorphisms in other immune molecules such as TLR4 26 and P2RX7 27 have been reported as candidate biomarkers predicting progression-free survival associated with chemotherapy-elicited cell death in breast cancer. The observed direction for prognosis is in the opposite direction that might be expected based on the binding affinities of the 2 alleles and might represent a chance finding. However, the considerably diverse expression of this receptor on a number of different immune cells (macrophages,γΔTcells, and many others) taken together with a wide variety of functions that often vary depending on the local microenvironment suggests that clinical outcomes can be very difficult to predict. We have shown that patients with breast cancer with 1 or 2o ft h eFCGR3A-158V alleles receive greater benefit from trastuzumab than patients who are homozygous for the FCGR3A-158F allele. Although multivariable analysis showed that patients with the F/F genotype had a slightly higher residual risk, this difference was not remarkable. Thus, genotyping does not seem to be sufficient for selection of patients for additional treatment.
Currently, many therapies, including new anti-ERBB2/ HER2 monoclonal antibodies or pan-tyrosine kinase inhibitors are being used in addition to trastuzumab to treat patients with breast cancer in the metastatic and neoadjuvant settings. These agents also engage the immune system and boost trastuzumab-induced ADCC.
28-30 Recent investigation of additional immune checkpoint inhibitors to anti-ERBB2/ HER2 therapies in patients with ERBB2/HER2-positive metastatic breast cancer is based on the hypothesis that a substantial component of trastuzumab benefit is mediated through ADCC and cross-priming of antigen-specific cytotoxic T cells, 22,23,31 which could enable the inhibition of immune checkpoints to improve the long-term efficacy of anti-ERBB2/ HER2 therapy. However, carefully designed clinical trials would be needed to determine if additional agents enhance trastuzumab activity in specific genotypes. Studies on NK cell mediated therapies suggest that the Fc region on monoclonal antibodies such as trastuzumab could be re-engineered to augment the affinity for a variety of inhibitory and activating FCGR allelotypes.
10,32,33 Single amino acid changes to the antibody at the binding site can strongly influence the binding strength. This notion also requires additional clinical studies.
Conclusions
This study supports the hypothesis that ADCC activity plays an important role in the efficacy of trastuzumab. However, a great number of different molecules are involved in determining ADCC activity, therefore it may be useful to collect peripheral blood monocytes from patients in future clinical trials so that functional ADCC activity can be assessed and associated with treatment efficacy of trastuzumab and other therapeutic monoclonal antibodies. For this analysis, the hi-affinity genotypes were combined (FCGR2A-HH or HR vs RR; FCGR3A-VV or VF vs FF) and multivariable estimates were adjusted for estrogen receptor (ER) (positive or negative) and nodal status (1-3, 4-9, or ≤10 positive lymph nodes). Due to missing ER status two patients were excluded from multivariable analysis of FCGR2A and three were excluded for FCGR3A. The box size is proportional to the precision.
